Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Neurofeedback Associated With Lower Scores on Numerous Depression Measures

Key clinical point: Neurofeedback augmentation consisting of medication and 12-24 sessions of neurofeedback training for 12 weeks improved symptoms in adults with treatment-resistant depression.

Major finding: Neurofeedback training reduced scores on several depression measures from baseline to 12 weeks, with response and remission rates of 58.3% and 50.0%, respectively. Also, changes in the Hamilton Depression Rating Scale, 5-level version of European Quality of Life Questionnaire 5-Dimensional Classification, and the Sheehan Disability Scale were significantly greater in the 12 patients assigned to neurofeedback augmentation, compared with the medication-only group.

Study details: The data come from an open-label, controlled study of 24 adults with treatment-resistant depression randomized to neurofeedback plus medication or medication only, and 12 healthy controls.

Disclosures: The researchers had no financial conflicts to disclose.

Citation:

Lee Y-J et al. J Korean Med Sci. 2019. doi: 10.3346/jkms.2019.34.e287.